ADARx Pharmaceuticals, Inc. ADRX
ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX) is a rare genetic drug developer. Its lead program, onvuzosiran, is in Phase 3 for Prevention of hereditary angioedema (HAE) attacks. Its next catalyst on record is onvuzosiran: STOP-HAE Phase 3 topline data (Q4 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: onvuzosiran — STOP-HAE Phase 3 topline data (Q4 2027). 9 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| onvuzosiran | Hereditary angioedema (PKK) | RNA (siRNA/ASO/mRNA) | Phase 3 |
| agazisiran | IgAN, C3G, IC-MPGN, PNH, geographic atrophy secondary to AMD (complement factor B) | RNA (siRNA/ASO/mRNA) | Phase 2 |
| ADX-626 | Secondary stroke prevention / stroke prevention in atrial fibrillation (Factor XI) | RNA (siRNA/ASO/mRNA) | Phase 1 |
| ADX-077 | Obesity (adipose-targeted, OBE1) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| ADX-199 | Alzheimer's disease / neurodegeneration (neuron-targeted APP) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.